Cisema at Asia Summit on Global Health 2026
Cisema was pleased to attend the Asia Summit on Global Health (ASGH) 2026 in Hong Kong, one of Asia's leading platforms for dialogue and collaboration across the healthcare and life sciences sectors.
The event brought together government representatives, regulators, healthcare providers, research institutions, investors, and industry leaders to explore emerging trends, regulatory developments, and innovation opportunities shaping the future of healthcare in the region. Discussions focused on improving healthcare access, strengthening research capabilities, accelerating innovation, and fostering greater cross-border collaboration throughout Asia.
Keynote Address by Chief Executive John KC Lee
In his opening remarks, Hong Kong Chief Executive John KC Lee highlighted the importance of international cooperation in addressing global healthcare challenges, including aging populations, antimicrobial resistance, and disparities in healthcare access.
He also outlined Hong Kong's vision to strengthen its position as a global healthcare innovation hub through several major regulatory and infrastructure initiatives.
Regulatory and Healthcare Development Initiatives
Key announcements included:
- Primary Evaluation for New Drug Registration – phased implementation underway, with full implementation targeted for 2030
- Regulatory modernization through the continued expansion of the "1+" registration mechanism
- Establishment of the Hong Kong Centre for Medical Products Regulation by the end of the year
- Expansion of government-supported clinical trial infrastructure
- Continued development of the Greater Bay Area (GBA) clinical trial and translational research ecosystem
Investment in Life Sciences and Innovation
The Chief Executive also highlighted significant investments designed to support healthcare innovation and industrial growth:
- New research facilities at the Hong Kong-Shenzhen Innovation and Technology Park (HSITP)
- A HK$10 billion (US$1.3 billion) New Industrialization Acceleration Scheme supporting high-end smart manufacturing facilities in Hong Kong
- An additional HK$10 billion (US$1.3 billion) strategic investment fund supporting five priority sectors, including life and health technologies
Looking Ahead
The announcements and discussions at ASGH 2026 reinforced Hong Kong's ambition to become a leading center for healthcare innovation, clinical research, and life sciences development. As regulatory frameworks continue to evolve and investment in the sector increases, new opportunities are emerging for organizations involved in medical devices, IVDs, clinical research, and healthcare technologies throughout the Asia-Pacific region.
For companies seeking to navigate these developments and successfully bring innovative products to market across Asia, contact Cisema today.